Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Yangwei Granules** is an orally administered traditional Chinese medicine granule product used for chronic gastritis, including chronic atrophic gastritis. It is a multi-herb medicinal preparation rather than a single defined chemical entity; reported botanical components include *Astragali Radix*, *Codonopsis Radix*, and *Nardostachyos Radix et Rhizoma*, among other Chinese herbal materials. The product has been marketed by Chiatai Qingchunbao Pharmaceutical, with retail listings identifying a 5 g granule presentation. No validated single molecular target or target-specific mechanism of action has been established for the full formulation. ([jd.com](https://www.jd.com/jiage/16206a1feb3a47b07b60.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangwei Granules.